Artios | search
Click here to view Artios news from 60+ newspapers.
Bookmark or Share- DNA Damage Response | DDR Company | Artios PharmaArtios is a leading independent DDR Company with a strong pipeline of novel cancer therapies in development with first-in-class & best-in-class potential.
- Artios initiates Phase 2 study of Polθ Inhibitor ART4215 in Combination ...Artios is building a pipeline of next-generation DDR programs to target hard to treat cancers, including its ATR inhibitor, ART0380, and the Polθ inhibitor, ART4215, as a monotherapy and with combination treatments.
- About Artios | Leadership | Scientific Advisors | BoardArtios is committed to discovering and developing groundbreaking DDR therapeutics to help patients suffering from a broad range of devastating and difficult-to-treat cancers. Innovation in this space is part of our DNA.
- Scientist (Ref: 4306) - Artios PharmaArtios Pharma is currently recruiting a Scientist to join our world class research team in a dynamic, expanding biotech company based south of Cambridge, UK. Artios is focused on identifying and developing cancer treatments by exploiting novel targets within the DNA damage response (DDR), a scientific area of high expectation following the ...
- Pipeline - Artios PharmaArtios is developing a leading franchise in inhibiting and understanding Polθ as a potent cancer target. Our Polθ program includes potentially first-in-class oral, potent, and highly selective reversible inhibitors targeting the Polθ polymerase domain.
More
